Last reviewed · How we verify

Janssen-Cilag Ltd.,Thailand — Portfolio Competitive Intelligence Brief

Janssen-Cilag Ltd.,Thailand pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
TTS-fentanyl TTS-fentanyl marketed
Tramadol HCI/acetaminophen Tramadol HCI/acetaminophen marketed Opioid analgesic combination Mu opioid receptor, norepinephrine transporter, serotonin transporter, COX inhibition Pain Management
Oxybutinin Extended-Release Oxybutinin Extended-Release marketed Anticholinergic agent Muscarinic acetylcholine receptor (M3) Urology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. University of California, Davis · 2 shared drug classes
  2. Albert Einstein College of Medicine · 1 shared drug class
  3. Edgar LeClaire, MD · 1 shared drug class
  4. Barrie Urology Associates · 1 shared drug class
  5. Children's Hospitals and Clinics of Minnesota · 1 shared drug class
  6. Daewon Pharmaceutical Co., Ltd. · 1 shared drug class
  7. Alza Corporation, DE, USA · 1 shared drug class
  8. Albany Medical College · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Janssen-Cilag Ltd.,Thailand:

Cite this brief

Drug Landscape (2026). Janssen-Cilag Ltd.,Thailand — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-cilag-ltd-thailand. Accessed 2026-05-18.

Related